Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Senseonics (NYSE:SENS) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the stock.

Senseonics Price Performance

Shares of NYSE SENS opened at $0.39 on Wednesday. The company has a quick ratio of 3.70, a current ratio of 3.96 and a debt-to-equity ratio of 1.79. The business’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.52. The company has a market cap of $208.00 million, a PE ratio of -2.80 and a beta of 0.82. Senseonics has a twelve month low of $0.37 and a twelve month high of $1.05.

Senseonics (NYSE:SENS) last issued its earnings results on Monday, May 13th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). Senseonics had a negative return on equity of 202.32% and a negative net margin of 346.38%. The company had revenue of $5.05 million during the quarter, compared to the consensus estimate of $4.76 million. On average, analysts predict that Senseonics will post -0.12 EPS for the current year.

Institutional Trading of Senseonics

Several hedge funds and other institutional investors have recently modified their holdings of SENS. RPO LLC acquired a new stake in Senseonics during the fourth quarter worth approximately $37,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after purchasing an additional 211,128 shares during the last quarter. State Board of Administration of Florida Retirement System bought a new stake in Senseonics in the 1st quarter valued at $91,000. Vanguard Group Inc. grew its holdings in Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in Senseonics by 16.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after buying an additional 51,000 shares during the period. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.